Duloxetine for the Treatment of Dysthymia

Not Recruiting

Trial ID: NCT00185575


The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.

Official Title

Duloxetine for the Treatment of Dysthymia

Stanford Investigator(s)

Elias Aboujaoude, MD, MA

Clinical Professor, Psychiatry and Behavioral Sciences


Inclusion Criteria::

   - Sign an informed consent form

   - 18 years of age or older

   - Females not pregnant or breastfeeding or planning pregnancy and using an acceptable
   form of contraception

   - Meet DSM-IV criteria for dysthymia

   - A screening IDS-C score of 17 or greater

   - No history of serious or unstable medical disorder

   - Not taking any significant concurrent medications

   - Not currently receiving psychotherapy Exclusion Criteria:- Suffering from DSM-IV

   - delirium, dementia, amnestic, or other cognitive disorders

   - mental disorders due to a general medical condition

   - factitious or somatoform disorders

   - mental retardation or developmental disabilities

   - substance or alcohol abuse within the last 3 months

   - depressive disorders with current suicidal risk

   - psychotic disorders including delusional disorder, somatic type

   - dissociative disorder

   - personality disorders sufficiently severe to interfere with study participation

   - History of DSM-IV defined bipolar I or II disorder

   - History of non-response of dysthymia to adequate antidepressant medication

   - History of major depression refractory to two adequate trials of antidepressants


drug: duloxetine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nona Gamel